Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France

Respiratory syncytial virus infection in macaques is not suppressed by intranasal sprays of pyrimidine biosynthesis inhibitors

(2016) Clément Grandin et al.   ANTIVIRAL RESEARCH

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy

(2016) Maria-Elisabeth Goebeler et al.   LEUKEMIA & LYMPHOMA

CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications

(2016) Anke Steinmetz et al.   mAbs

CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands

(2016) Bruno Lamas et al.   NATURE MEDICINE

A Novel Nonhuman Primate Model of Cigarette Smoke–Induced Airway Disease

(2015) Francesca Polverino et al.   AMERICAN JOURNAL OF PATHOLOGY

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

(2015) Laurent Detalle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Protective role for club cell secretory protein-16 (CC16) in the development of COPD

(2015) Maria E. Laucho-Contreras et al.   EUROPEAN RESPIRATORY JOURNAL

Cigarette Smoke Silences Innate Lymphoid Cell Function and Facilitates an Exacerbated Type I Interleukin-33-Dependent Response to Infection

(2015) Jennifer Kearley et al.   IMMUNITY

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

(2015) Nick Thatcher et al.   LANCET ONCOLOGY

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

(2015) Luis Paz-Ares et al.   LANCET ONCOLOGY

Antibodies to watch in 2016

(2015) Janice M. Reichert   mAbs

Corrigendum: The receptor NLRP3 is a transcriptional regulator of TH2 differentiation

(2015) Mélanie Bruchard et al.   NATURE IMMUNOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation

(2015) Fahima Madouri et al.   Journal of Molecular Cell Biology

Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation

(2015) E. Suzanne Cohen et al.   Nature Communications

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

(2015) Maria E. Laucho-Contreras et al.   Jove-Journal of Visualized Experiments

Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab

(2015) Rita De Santis et al.   Oncotarget

Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia

(2014) Y.-A. Que et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract

(2014) Salome Juliette Koussoroplis et al.   JOURNAL OF CONTROLLED RELEASE

Evidence for an intranasal immune response to human respiratory syncytial virus infection in cynomolgus macaques

(2014) C. Grandin et al.   JOURNAL OF GENERAL VIROLOGY

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

(2014) Virginie Hervé et al.   mAbs

Effect of formulation on the stability and aerosol performance of a nebulized antibody

(2014) Renaud Respaud et al.   mAbs

Bifunctional Lipocalin Ameliorates Murine Immune Complex-induced Acute Lung Injury

(2013) Pietro Roversi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

(2013) K. Tamura et al.   JOURNAL OF NUCLEAR MEDICINE

The Anti-Pseudomonas aeruginosa Antibody Panobacumab Is Efficacious on Acute Pneumonia in Neutropenic Mice and Has Additive Effects with Meropenem

(2013) Thomas Secher et al.   PLoS One

An Anti-Human ICAM-1 Antibody Inhibits Rhinovirus-Induced Exacerbations of Lung Inflammation

(2013) Stephanie Traub et al.   PLoS Pathogens

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

(2013) Lui G Franciosi et al.   Lancet Respiratory Medicine

The Discovery, Engineering and Characterisation of a Highly Potent Anti-Human IL-13 Fab Fragment Designed for Administration by Inhalation

(2012) Daniel Lightwood et al.   JOURNAL OF MOLECULAR BIOLOGY

The potential of biologics for the treatment of asthma

(2012) Girolamo Pelaia et al.   NATURE REVIEWS DRUG DISCOVERY

Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection

(2011) T. Secher et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inflammasome-IL-1-Th17 response in allergic lung inflammation

(2011) A.-G. Besnard et al.   Journal of Molecular Cell Biology

Airway responsiveness in an allergic rabbit model

(2011) S.D. Keir et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Preclinical In Vitro and In Vivo Characterization of the Fully Human Monoclonal IgM Antibody KBPA101 Specific for Pseudomonas aeruginosa Serotype IATS-O11

(2010) M. P. Horn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Biochemical and Biological Characterization of a New Oxidized Avidin with Enhanced Tissue Binding Properties

(2010) Antonio Verdoliva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging

(2009) E. C.F. Dijkers et al.   JOURNAL OF NUCLEAR MEDICINE

Development trends for therapeutic antibody fragments

(2009) Aaron L Nelson et al.   NATURE BIOTECHNOLOGY